Literature DB >> 24134499

Staging of intestinal- and diffuse-type gastric cancers with the OLGA and OLGIM staging systems.

S-J Cho1, I J Choi, M-C Kook, B-H Nam, C G Kim, J Y Lee, K W Ryu, Y-W Kim.   

Abstract

BACKGROUND: Operative link on gastritis assessment (OLGA) and Operative link on gastric intestinal metaplasia assessment (OLGIM) staging systems have been proposed for gastric cancer (GC) risk estimation. AIM: To validate the OLGA and OLGIM staging systems in a region with high risk of GC.
METHODS: This retrospective study included 474 GC patients and age- and sex-matched health screening control persons in a cancer centre hospital. We classified gastritis patterns according to the OLGA and OLGIM systems using the histological database that a pathologist prospectively evaluated using the updated Sydney system. GC risk according to the OLGA and OLGIM stages was evaluated using logistic regression analysis.
RESULTS: More GC patients had OLGA stages III-IV (46.2%) than controls (26.6%, P < 0.001), particularly among patients with intestinal-type GCs (62.2%) compared with diffuse-type GCs (30.9%). OLGA stages III and IV were significantly associated with increased risk of GC [odds ratios (ORs), 2.09; P = 0.008 and 2.04; P = 0.014 respectively] in multivariate analysis. The association was more significant for intestinal-type (ORs, 4.76; P = 0.001 and 4.19; P = 0.002 respectively), but not diffuse-type GC. OLGIM stages from I to IV were significantly associated with increased risk of both intestinal-type (ORs, 3.64, 5.15, 7.89 and 13.20 respectively) and diffuse-type GC (ORs, 1.84, 2.59, 5.08 and 6.32 respectively) with a significantly increasing trend.
CONCLUSION: As high OLGA and OLGIM stages are independent risk factors for gastric cancer, the staging systems may be useful for risk assessment in high-risk regions, especially for intestinal-type gastric cancer.
© 2013 John Wiley & Sons Ltd.

Entities:  

Mesh:

Year:  2013        PMID: 24134499     DOI: 10.1111/apt.12515

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  20 in total

1.  The significance of OLGA and OLGIM staging systems in the risk assessment of gastric cancer: a systematic review and meta-analysis.

Authors:  Hu Yue; Liu Shan; Lv Bin
Journal:  Gastric Cancer       Date:  2018-02-19       Impact factor: 7.370

Review 2.  Screening for and surveillance of gastric cancer.

Authors:  Debora Compare; Alba Rocco; Gerardo Nardone
Journal:  World J Gastroenterol       Date:  2014-10-14       Impact factor: 5.742

Review 3.  The risk of diffuse-type gastric cancer following diagnosis with gastric precancerous lesions: a systematic review and meta-analysis.

Authors:  John E Wang; Sung Eun Kim; Bong Eun Lee; Sungho Park; Joo Ha Hwang; Robert J Huang
Journal:  Cancer Causes Control       Date:  2021-11-19       Impact factor: 2.506

4.  OLGA- and OLGIM-Based Staging in the Patients with Gastritis and Endoscopy Indications.

Authors:  Fariborz Mansour-Ghanaei; Farahnaz Joukar; Sara Yeganeh; Mahbobeh Sadeghi; Arash Daryakar; Masood Sepehrimanesh
Journal:  Turk J Gastroenterol       Date:  2022-02       Impact factor: 1.555

5.  Tumorigenic mechanisms of estrogen and Helicobacter pylori cytotoxin-associated gene A in estrogen receptor α-positive diffuse-type gastric adenocarcinoma.

Authors:  Seungkyung Kang; Miree Park; Jung Yeon Cho; Su Jin Ahn; Changhwan Yoon; Sang Gyun Kim; Soo-Jeong Cho
Journal:  Gastric Cancer       Date:  2022-04-07       Impact factor: 7.701

6.  KMT2C Mutations in Diffuse-Type Gastric Adenocarcinoma Promote Epithelial-to-Mesenchymal Transition.

Authors:  Soo-Jeong Cho; Changhwan Yoon; Jun Ho Lee; Kevin K Chang; Jian-Xian Lin; Young-Ho Kim; Myeong-Cherl Kook; Bülent Arman Aksoy; Do Joong Park; Hassan Ashktorab; Duane T Smoot; Nikolaus Schultz; Sam S Yoon
Journal:  Clin Cancer Res       Date:  2018-08-14       Impact factor: 12.531

7.  High-risk individuals for gastric cancer would be missed for surveillance without subtyping of intestinal metaplasia.

Authors:  Sergejs Isajevs; Selga Savcenko; Inta Liepniece-Karele; Maria Blanca Piazuelo; Ilze Kikuste; Ivars Tolmanis; Aigars Vanags; Indra Gulbe; Linda Mezmale; Darhan Samentaev; Altynbek Tazedinov; Ramis Samsutdinov; Tatjana Belihina; Nurbek Igissinov; Marcis Leja
Journal:  Virchows Arch       Date:  2021-05-14       Impact factor: 4.064

Review 8.  Endoscopic gastric cancer screening and surveillance in high-risk groups.

Authors:  Il Ju Choi
Journal:  Clin Endosc       Date:  2014-11-30

Review 9.  Diagnosis and management of high risk group for gastric cancer.

Authors:  Hyuk Yoon; Nayoung Kim
Journal:  Gut Liver       Date:  2015-01       Impact factor: 4.519

10.  Atrophic and Metaplastic Progression in the Background Mucosa of Patients with Gastric Adenoma.

Authors:  Hee Kyong Na; Charles J Cho; Suh Eun Bae; Jeong Hoon Lee; Young Soo Park; Ji Yong Ahn; Do Hoon Kim; Kee Don Choi; Ho June Song; Gin Hyug Lee; Se Jin Jang; Hwoon-Yong Jung
Journal:  PLoS One       Date:  2017-01-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.